Last updated: 07/17/2024 17:28:46

Safety, clinical activity, pharmacokinetics (PK) and pharmacodynamics study of GSK2879552, alone or with azacitidine, in subjects with high risk myelodysplastic syndromes (MDS)

GSK study ID
205744
See study documents
Clinicaltrials.gov ID
NCT02929498
See results summary
EudraCT ID
2016-002294-35
EU CT Number
Not applicable
Trial status
Other
Other
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A phase I/II, open-label, 2 arm study to investigate the safety, clinical activity, pharmacokinetics and pharmacodynamics of GSK2879552 administered alone or in combination with azacitidine, in adult subjects with IPSS-R high and very high risk myelodysplastic syndromes (MDS) previously treated with hypomethylating agents (HMA)
Trial description: This is a Phase I/II, open-label, 2 arm study to evaluate the safety and clinical activity of GSK2879552 alone, or in combination with azacitidine in subjects with MDS. The study consisted of 2 parts. The objective of Part 1 is to determine the recommended phase 2 dose (RP2D) of GSK2879552 administered alone and in combination with azacitidine in adult subjects with high risk MDS previously treated with HMA. The objective of Part 2 is to evaluate clinical activity after treatment with GSK2879552, alone or in combination with azacitidine, in adult subjects with high risk MDS previously treated with HMA.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:

Part 1: Number of subjects with any adverse events (AEs) and any serious adverse events (SAEs)

Timeframe: Up to 2.5 years

Part 1: Number of subjects with dose limiting toxicities, dose reductions or delays, and withdrawals due to toxicities

Timeframe: Up to 2.5 years

Part 1: Number of subjects with abnormal laboratory values

Timeframe: Up to 2.5 years

Part 1: Number of subjects with abnormal vital signs

Timeframe: Up to 2.5 years

Part 1: Number of subjects with abnormal electrocardiograms (ECGs)

Timeframe: Up to 2.5 years

Part 1: Number of subjects with abnormal physical examinations

Timeframe: Up to 2.5 years

Part 2: Clinical benefit rate (CBR)

Timeframe: Up to 2.5 years

Part 2: Objective response rate (ORR)

Timeframe: Up to 2.5 years

Secondary outcomes:

Part 1: CBR

Timeframe: Up to 2.5 years

Part 1: ORR

Timeframe: Up to 2.5 years

Part 1: Assessment of GSK2879552 concentrations

Timeframe: Up to 48 weeks

Part 1: Assessment of azacitidine concentrations

Timeframe: Up to 48 weeks

Part 1: Duration of response (DOR)

Timeframe: Up to 2.5 years

Part 1: Progression-free survival (PFS)

Timeframe: Up to 2.5 years

Part 1: Overall survival (OS)

Timeframe: Up to 2.5 years

Part 1: Percentage of subjects with disease progression to acute myeloid leukemia (AML)

Timeframe: Up to 2.5 years

Part 1: Time to AML progression

Timeframe: Up to 2.5 years

Part 1: Number of documented platelet and red blood cell (RBC) transfusions per month prior to study entry and during study

Timeframe: Up to 2.5 years

Part 2: Number of subjects with any AEs and any SAEs

Timeframe: Up to 2.5 years

Part 2: Number of subjects with abnormal laboratory values

Timeframe: Up to 2.5 years

Part 2: Number of subjects with abnormal vital signs

Timeframe: Up to 2.5 years

Part 2: Number of subjects with abnormal ECGs

Timeframe: Up to 2.5 years

Part 2: Number of subjects with abnormal physical examinations

Timeframe: Up to 2.5 years

Part 2: Population PK parameter of clearance (CL/F) for GSK2879552

Timeframe: Up to 48 weeks

Part 2: DOR

Timeframe: Up to 2.5 years

Part 2: PFS

Timeframe: Up to 2.5 years

Part 2: OS

Timeframe: Up to 2.5 years

Part 2: Percentage of subjects with disease progression to AML

Timeframe: Up to 2.5 years

Part 2: Time to AML progression

Timeframe: Up to 2.5 years

Part 2: Number of documented platelet and RBC transfusions per month prior to study entry and during study

Timeframe: Up to 2.5 years

Interventions:
  • Drug: GSK2879552
  • Drug: Azacitidine
    • Enrollment:
    7
    Primary completion date:
    2018-31-01
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Myelodysplastic syndrome
    Product
    GSK2879552, azacitidine
    Collaborators
    Parexel International
    Study date(s)
    July 2017 to January 2018
    Type
    Interventional
    Phase
    2

    Participation criteria

    Sex
    Female & Male
    Age
    18+ years
    Accepts healthy volunteers
    No
    • >=18 years of age and provided signed written informed consent
    • Subjects must have IPSS-R high or very high risk myelodysplastic syndromes (MDS) by World Health Organization (WHO) classification
    • AML according to world health organization (WHO) criteria (i.e. bone marrow blasts >20%)
    • Active hepatitis B or hepatitis C treatment
    Inclusion and exclusion criteria
    Inclusion criteria:
    • >=18 years of age and provided signed written informed consent
    • Subjects must have IPSS-R high or very high risk myelodysplastic syndromes (MDS) by World Health Organization (WHO) classification
    • Subjects must have failed hypomethylating treatment where “failure” is defined as: Progression (according to 2006 International Working Group [IWG] criteria) at any time after initiation of the hypomethylating treatment OR Failure to achieve complete or partial response or hematological improvement (HI) (according to 2006 IWG) after at least 4 cycles treatment OR Relapse after initial complete or partial response or HI (according to 2006 IWG criteria).
    • Subjects are not a candidate, or have failed allogeneic stem cell transplantation. Subjects who underwent allo-transplant in the past are eligible under following conditions: transplant was >2 year prior to enrolment, and no evidence of active graft-versus-host disease (GVHD)
    • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
    • Subjects must have a life expectancy of at least 12 weeks, in the opinion of the investigator.
    • Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
    • All prior treatment-related toxicities must be National Cancer Institute- Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 4.0 <=Grade 1 at the time of enrollment (except for alopecia).
    • Adequate baseline organ function defined by: International Normalization Ratio (INR) and activated partial thromboplastin time (aPTT) <=1.3xupper limit of normal (ULN); platelet count (PLT) >=10,000 (transfusions permitted to bring PLT to >10,000); total bilirubin <=1.5xULN (Isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35% or subject has a diagnosis of Gilbert’s syndrome); Alanine transaminase (ALT) <=2.5xULN; creatinine <=1.5xULN OR calculated creatinine clearance by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation or measured from 24 hour urine >=50 milliliters (mL)/minute (min); and Ejection fraction >=lower limit of normal (LLN) by Echocardiogram (ECHO) or multigated acquisition scan (MUGA)
    • Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception during the study and for 7 days following the last dose of study treatment.
    • Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from the administration of the first dose of study treatment until 3 months after the last dose of study treatment to allow for clearance of any altered sperm.
    Exclusion criteria:
    • AML according to world health organization (WHO) criteria (i.e. bone marrow blasts >20%)
    • Active hepatitis B or hepatitis C treatment
    • Baseline Montreal Cognitive Assessment (MOCA) score of 22 or lower
    • History of or concurrent malignancy of solid tumours, except for below: Exception: Subjects who have been disease-free for 2 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
    • Prior treatment with temozolomide, dacarbazine or procarbazine
    • Prior treatment with poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitors (example (e.g.), olaparib, veliparib [ABT-888])
    • Currently receiving other anti-cancer therapy (chemotherapy, radiation therapy, immuno- therapy, biologic therapy, hormonal therapy, surgery, and/or tumour embolization)
    • Received major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK2879552 administration
    • Evidence of severe or uncontrolled systemic diseases (e.g., severe/chronic infection, unstable or uncompensated respiratory, renal, or cardiac disease). Any serious and/or unstable pre-existing medical (aside from malignancy exception above), psychiatric disorder, or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study procedures, in the opinion of the Investigator
    • Current active liver or biliary disease (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator’s assessment)
    • Patients with any major bleeding current or within the past 4 weeks. (e.g. recent gastrointestinal [GI] hemorrhage or neurosurgery).
    • Administration of an investigational drug within 14 days or 5 half-lives, whichever is shorter, preceding the first dose of study treatment(s) in this study.
    • Cardiac abnormalities as evidenced by any of the following: clinically significant uncontrolled arrhythmias or uncontrolled hypertension; history or evidence of current >=Class II congestive heart failure as defined by New York Heart Association (NYHA); history of acute coronary syndromes (including unstable angina and myocardial infarction), coronary angioplasty, or stenting within the past 3 months; baseline Corrected QT (QTc) interval using Fridericia’s formula >450 milliseconds (msec) or >480 msec in subjects with Bundle Branch Block. QTc value based on single or average of triplicate ECGs obtained over a brief recording period
    • Current use of a prohibited medication including anticoagulants or platelet inhibitors or expected to require any of these medications during treatment with the investigational drug
    • Consumption of Seville oranges, grapefruit, grapefruit hybrids, grapefruit juice, pommelos, or exotic citrus fruits, from 1 day prior to the first dose of study treatment(s) until the last dose of study drug
    • Lactating female
    • Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK2879552 or lysine-specific demethylase 1 (LSD1) inhibitors that contraindicates their participation
    • Known hypersensitivity to azacitidine or mannitol

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Augusta, Georgia, United States, 30912
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    Houston, Texas, United States, 77030
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    Madrid, Spain, 28033
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    Philadelphia, Pennsylvania, United States, 19111
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    Valencia, Spain, 46026
    Status
    Study Complete
    Contact us

    Study documents

    Clinical study report
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Results posted on ClinicalTrials.gov

    Recruitment status
    Other
    Actual primary completion date
    2018-31-01
    Actual study completion date
    2018-31-01

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Additional information
    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website